We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
Unlock the market timeline & signal feed
New Partnerships activity — 2 fresh signals just appeared.
The order this company entered each market — oldest to newest
59 active postings
10 active postings
Sign up to see the full signal feed
How Pfizer's international expansion compares to its competitors
PfizerYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 PfizerYou | 41 | 3 | +78% | 161 | 57 |
Analista Marketing & Soluções Saúde Pl - Medicina Interna
View postingSão Paulo, São Paulo, Brazil · today
Safety Surveillance Associate with English and French
View postingWarsaw, Mazowieckie, Poland · today
Staff Platform Engineer, AI/ML Infrastructure
View postingParis, Île-de-France, France · today
Register Today
Ended
In Belgium alone, nearly 80,000 people are diagnosed with cancer every year — and this number continues to rise. According to the latest figures from the Belgian Cancer Registry, diagnoses could increase by 21% by 2035, reaching around 93,000 cases annually — the equivalent of 44 additional diagnoses every single day compared to 2023. Behind these numbers are people, families, and lives disrupted in an instant. This is why moments like the American Society of Clinical Oncology (ASCO) Annual Meet ...
EndedFake News, pourquoi on y croit ? Quand la désinformation se fait science
EndedGoodRx's Pharma Direct unit grew 82% YoY in Q1, handling one-third of Wegovy pill transactions. The platform connects pharmaceutical manufacturers directly to consumers through point-of-sale pricing programs.
Johnson & Johnson's Erleada combined with hormone therapy before and after prostate surgery reduced cancer progression risk by 20% and improved cancer elimination chances ninefold in late-stage trial.
Ascentage Pharma presented updated efficacy and safety data for Olverembatinib (HQP1351) as second-line CML-CP treatment at ASCO 2026, showing 91.3% CCyR and 60.9% MMR at 24 cycles with manageable safety profile.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Pfizer's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
